Fax: 47 67 12 26 58
72 articles with Targovax
Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces its fourth quarter and full year 2018 results.
Extends IP protection of TG01 and TG02 until 06.05.2034
Targovax (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic Healthcare Conference in Oslo, Norway.
Targovax ASA announces that members of its senior management will present at the following life sciences and investor conferences
Targovax ASA today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston
Targovax ASA today announces its third quarter 2018 results.
Targovax ASA will announce its third quarter 2018 results on Thursday, 1 November 2018 at 07:00 CET.
Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer
16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial
Presentation of full TG01 phase I/II clinical trial results in resected pancreatic cancer, by Professor Daniel Palme
Symposium faculty to include Dmitriy Zamarin, MD, PhD, and Alexander N. Shoushtari, MD, medical oncologists from Memorial Sloan Kettering Cancer Center
Presentation of full TG01 phase I/II clinical trial results in resected pancreatic cancer, by Professor Daniel Palmer
Targovax ASA announces that the Company presented at the following conference:
Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
Targovax ASA announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018.
Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy
Validation of ONCOS-102 potential to generate tumor-specific immune responses in vivo
Targovax ASA announces its second quarter and first half year 2018 results.
Targovax ASA: Invitation to Second Quarter and First Half Year 2018 Results Presentation Thursday 23 August
Targovax ASA will announce its second quarter and first half year 2018 results on Thursday, 23 August 2018. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET.
Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC
Targovax and SOTIO announce the first patient has been dosed with ONCOS-102 in the SP015 phase I/II clinical trial in patients with prostate cancer, combining the Company's immune-priming adenovirus ONCOS-102, with SOTIO's DCVAC/PCa, an active cellular immunotherapy.
Provides IP protection of TG02 in Europe until 09.12.2033
Targovax ASA hosts a conference call to give an update to its clinical development strategy.
Recent clinical data is driving increased interest in the industry for oncolytic viruses as an emerging class of cancer therapeutics